Pancrelipase controlled-release - Digestive Care

Drug Profile

Pancrelipase controlled-release - Digestive Care

Alternative Names: PANCRECARB® MS-16; Pancrelipase delayed release capsules - Digestive Care; Pertzye; Pertzyme

Latest Information Update: 14 Oct 2016

Price : $50

At a glance

  • Originator Digestive Care
  • Class Pancreatic enzymes
  • Mechanism of Action Enzyme replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Exocrine pancreatic insufficiency

Most Recent Events

  • 12 Oct 2016 Launched for Exocrine pancreatic insufficiency (In infants) in USA in October 2016 (PO, 4000 USP lipase units/capsule)
  • 11 Oct 2016 Registered for Exocrine pancreatic insufficiency (In infants) in USA in October 2016 (PO, 4000 USP lipase units/capsule)
  • 28 Apr 2014 Cornerstone Therapeutics is now called Chiesi USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top